GLP-1 Insurance Coverage Guide: Clinical Eligibility & Biomarkers

Last reviewed: May 21, 2026

Last updated: May 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medication insurance coverage typically requires documented medical need, a BMI ≥30 or ≥27 with comorbidities, and completion of prior authorization. Most major insurers now cover these medications for weight management and type 2 diabetes, though approval timelines and formulary restrictions vary significantly by plan.

Securing coverage goes beyond meeting baseline criteria—understanding your individual clinical profile, metabolic markers, and genetic predispositions can strengthen your case. PlexusDx emphasizes precision-wellness approaches that align your medication strategy with your unique biochemistry, making coverage conversations with providers more informed and evidence-based.

Insurance Coverage Landscape for GLP-1 Medications

Major insurers including UnitedHealthcare, Aetna, Cigna, and Humana now cover GLP-1 medications for weight management and type 2 diabetes, though coverage policies continue evolving. Most require prior authorization and documented medical necessity, including baseline BMI, previous weight-loss attempts, and comorbidity confirmation.

Coverage approval rates average 70-85% for patients meeting clinical criteria, but rejection and appeal cycles can extend timelines by 30-60 days. Understanding your specific plan's formulary tier, step-therapy requirements, and appeal process reduces delays and denial risk.

Clinical Eligibility Criteria That Drive Insurance Approval Decisions

Insurance companies evaluate GLP-1 eligibility using standardized medical necessity criteria. These typically include BMI documentation, failure of previous weight-loss interventions, documented cardiometabolic disease, and provider clinical justification. Meeting multiple criteria strengthens approval likelihood.

Eligibility Factor	Typical Requirement for Coverage
BMI Threshold	≥30 kg/m² or ≥27 with comorbidity (hypertension, diabetes, sleep apnea)
Prior Weight-Loss Attempts	Documented history of diet, exercise, or previous medications
Comorbidity Documentation	Type 2 diabetes, cardiovascular disease, or obesity-related condition
Provider Justification	Clinical note explaining medical necessity and expected benefit
Step-Therapy Compliance	Some plans require failed metformin or other agents first
Age Requirements	Most plans cover adults 18+; some have upper age limits

Biomarkers and Genetic Context: Strengthening Your Coverage Narrative

Insurance reviewers increasingly recognize that GLP-1 response varies by individual metabolic and genetic profile. Documenting relevant biomarkers—fasting glucose, HbA1c, triglycerides, inflammatory markers, and genetic predispositions in peptide pathways—creates a more compelling clinical case for approval.

The Precision Peptide Genetic Test reveals individual predispositions in GLP-1R, GIPR, FTO, and MC4R pathways, which may help provide context for personalized medication selection. While genetics cannot predict exact medication response, discussing these pathway predispositions with your provider can support a more evidence-informed conversation with insurance reviewers about why GLP-1 therapy aligns with your biology.

Prior Authorization Strategy and Appeals Process

Prior authorization is required by most insurers before GLP-1 dispensing. Submit complete documentation including BMI, relevant labs, weight-loss history, and provider clinical notes. Incomplete submissions are the leading cause of initial denials—expect 5-10 business days for initial review.

If denied, appeal immediately with additional clinical evidence: updated biomarkers, comorbidity records, or genetic predisposition context. Roughly 60% of initial denials are overturned on appeal. Request expedited review if medically urgent; provide peer-reviewed literature supporting GLP-1 efficacy for your specific indication.

Out-of-Pocket and Compounded Medication Options When Insurance Denies Coverage

If insurance denies coverage or imposes unaffordable copays, compounded GLP-1 medications offer a lower-cost alternative. PlexusDx compounded semaglutide and tirzepatide range from $149/mo monthly—often 40-60% less than branded alternatives or insurance out-of-pocket maximums.

Compounded medications sourced from licensed 503A pharmacies provide medical-grade options without the branded markup. Discuss with your provider whether compounded therapy aligns with your clinical profile and coverage situation. Many patients use compounded medications while continuing insurance appeals or as a bridge during authorization delays.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic insights—specifically predispositions in GLP-1R, GIPR, FTO, and MC4R pathways—may help provide context for why GLP-1 therapy aligns with your individual biology. When discussing coverage with insurers, this information can support a more personalized narrative about expected medication response and clinical rationale. Should be interpreted with a qualified healthcare provider.

The Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals these pathway predispositions, which can contextualize your medication selection and clinical profile. Genetic predispositions do not predict exact medication response or guarantee coverage approval, but they support evidence-informed conversations between you and your provider about which GLP-1 formulation may align best with your biochemistry.

When building a coverage case, having biomarker data and genetic context strengthens your clinical narrative. PlexusDx helps you understand your individual peptide pathway profile, which your provider can then present to insurance reviewers as part of a comprehensive, personalized medical justification for GLP-1 therapy approval.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.